AstraZeneca logo
  • THERAPEUTIC AREAS
    • ONCOLOGY
    • R&I
    • CVRM
  • PRODUCTS
  • ABOUT US
  • FASENRA
    • Home
    • Efficacy Profile & Clinical Trials
    • About FASENRA®
    • Dosing & Administration
    • Resources
    • Safety Information
  • SYMBICORT
    • Home
    • Disease Burden
    • Efficacy Profile & Clinical Trials
    • Safety Profile
    • Mechanism of Action
    • Dosing & Administration
    • Resources
    • Safety Information
    • Product Monograph
    • Resources Patient
    • Resources HCP
    • home
    • Home Pharmacist
    • Home CRE RT
    • Safety Information 1
    • Home Physician
  • TEZSPIRE
    • Home
    • Efficacy Profile & Clinical Trials
    • Mechanism of Action
    • Dosing & Administration
    • Resources
    • Safety Information
    • NAVIGATOR study
    • PATHWAY study
    • Resources
  • TRUQAP
    • Home
    • Testing for Biomarkers
    • Efficacy Data & Pivotal Clinical Trial
    • Safety Profile
    • Mechanism of Action
    • Dosing & Administration
    • Resources & Ongoing Trials
    • Safety Information
    • Product Monograph
    • Efficacy data & Pivotal Clinical Trial
  • AZ Authentics
    • Home
    • What Is AstraZeneca Authentics?
    • How Does AstraZeneca Authentics Work?
    • Eligible AstraZeneca Brands
    • FAQ
  • test22
  • test33
  • Patient Profiles
Login/Register
  • TEZSPIRE
  • Home

Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR

Tezspire logo

Think TEZSPIRE®

for patients with severe asthma

Patient text

TEZSPIRE® (tezepelumab injection) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma. TEZSPIRE® is not indicated for relief of acute bronchospasm or status asthmaticus.
Download the TEZSPIRE® Product Monograph Teach your patients how to use TEZSPIRE®
  • Efficacy Profile &

    Clinical Trials

    Explore Efficacy Profile & Clinical Trials

  • Mechanism
    of Action

    Explore Mechanism of Action

  • Dosing
    & Administration

    Explore Dosing & Administration

  • Resources

    Explore Resources

Connect360 Patient Support Program Resources

The Connect360 Patient Support Program provides resources designed to support your patients and help them manage their severe asthma.

Interested in learning more?

  • Call the Connect360 Patient Support Program at 1 (833) 360-2666

  • Email
    connect360@innomar-strategies.com

  • Monday to Friday:
    8 am to 8 pm (EST)

Quick Links

  • Explore the NAVIGATOR and PATHWAY pivotal clinical trial data

    Explore clinical trial data

  • Review the safety profile
    for TEZSPIRE®

    Review safety profile

Amgen logoTezspire logo

TEZSPIRE® and the logo are trademarks of Amgen Inc. and the Amgen logo is a registered trademark of Amgen Inc., used under license by AstraZeneca Canada Inc.

CA-8885E. Last updated 10/24

AstraZeneca logo

© 2024 AstraZeneca Canada Inc. All rights reserved.

AstraZeneca and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

CA-8890E

  • Legal Notice and Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
PAAB logoIMC logo

TEZSPIRE® and the logo are trademarks of Amgen Inc. and the Amgen logo is a registered trademark of Amgen Inc., used under license by AstraZeneca Canada Inc.

CA-8885E. Last updated 06/24

© 2024 AstraZeneca Canada Inc. All rights reserved.

AstraZeneca and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

CA-8890E

  • Legal Notice and Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us

Blueprint HCP Portal

La información contenida en este sitio web está dirigida exclusivamente a profesional sanitario facultado para prescribir o dispensar medicamentos en España (requiere una formación especializada para su correcta interpretación)AstraZeneca promueve la prescripción de sus productos farmacéuticos en las condiciones establecidas en su ficha técnica.

NO